07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Clinical News

DexaSite dexamethasone: Phase III data

Top-line data from the double-blind, U.S. Phase III DOUBle trial in 907 patients with moderate to severe blepharitis showed that AzaSite Plus and DexaSite each missed the primary endpoint of complete resolution of all...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Clinical News

AzaSite Plus: Phase III data

Top-line data from the double-blind, U.S. Phase III DOUBle trial in 907 patients with moderate to severe blepharitis showed that AzaSite Plus and DexaSite each missed the primary endpoint of complete resolution of all clinical...
07:00 , Jul 29, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Forest Laboratories Inc. (NYSE:FRX) was up $0.42 to $44.41 on Friday after FDA approved Fetzima levomilnacipran to treat major depressive disorder (MDD) in adults. The company said the product will be available in the...
00:52 , Jul 24, 2013 |  BC Extra  |  Clinical News

InSite reports Phase III blepharitis data

InSite Vision Inc. (OTCBB:INSV) said twice-daily AzaSite Plus and DexaSite dexamethasone for 14 days each missed the primary endpoint of complete resolution of all clinical signs and symptoms of blepharitis at day 15 vs. AzaSite...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

2Q13 Financial Markets Preview: Manning the middle

Buysiders are being drawn to mid- and small cap biotechs with solid balance sheets and/or near-term inflection points going into 2Q13, a period that may be relatively quiet for some of the sector's largest names. The...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

DexaSite dexamethasone: Completed Phase III enrollment

InSite completed enrollment of over 900 patients the double-blind, U.S. DOUBle Phase III trial to evaluate AzaSite Plus and DexaSite. Patients are receiving AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

AzaSite Plus: Completed Phase III enrollment

InSite completed enrollment of over 900 patients the double-blind, U.S. DOUBle Phase III trial to evaluate AzaSite Plus and DexaSite. Patients are receiving AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Clinical News

DexaSite dexamethasone: Phase III delayed

InSite said in its 2Q12 earnings that it will delay until further notice the start of a Phase III trial to evaluate DexaSite to save cash and focus on ongoing Phase III DOUBle trial to...
08:00 , Dec 19, 2011 |  BioCentury  |  Regulation

Europe speeds away

The European Commission's new action plan to combat antimicrobial resistance could further widen the regulatory gap between the U.S. and Europe, which is already at the point where some physicians worry companies will no longer...